Share-based Compensation

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

The Corporation maintains share-based compensation plans under which it periodically grants share-based awards for a fixed number of shares to certain officers of the Corporation.

Before the Merger, Chemical and Legacy TCF granted share-based awards under their respective share-based compensation plans, including the Chemical Stock Incentive Plan of 2019 (the "Stock Incentive Plan of 2019”") and the TCF Financial 2015 Omnibus Incentive Plan (the "Legacy TCF Omnibus Incentive Plan"). At March 31, 2020, there were 2,271,926 shares reserved for issuance under the Legacy TCF Omnibus Incentive Plan and there were 1,791,840 shares reserved for issuance under the Stock Incentive Plan of 2019.

The fair value of share-based awards is recognized as compensation expense over the requisite service or performance period. Compensation expense for share-based awards was $4.7 million for the three months ended March 31, 2020 and $2.3 million for the same period in 2019. The excess tax benefit realized from share-based compensation transactions during the three months ended March 31, 2020 was a benefit of $677 thousand and $704 thousand for the same period in 2019.

Restricted Stock Units

The Corporation can grant performance-based restricted stock units ("PRSUs") and time-based restricted stock units ("TRSUs") (collectively referred to as "RSUs") under the Stock Incentive Plan of 2019 and the Legacy TCF Omnibus Incentive Plan; provided, that, RSUs granted under the Legacy TCF Omnibus Incentive Plan may only be granted to employees who previously were employees of Legacy TCF. At March 31, 2020, there were no PRSUs outstanding dependent on achieving certain performance target levels and the grantee completing the requisite service period. The TRSUs vest upon satisfaction of a service condition. Upon achievement of the performance target level and/or satisfaction of a service condition, as applicable, the RSUs are converted into shares of TCF Financial's common stock on a one-to-one basis. Compensation expense related to RSUs is recognized over the expected requisite performance or service period, as applicable.

A summary of the activity for RSUs at and for the three months ended March 31, 2020 is presented below:



	Number of Units		Weighted-average Grant Date Fair Value Per Unit
Outstanding at December 31, 2019	1,511,820		$	44.49
Granted	16,980		39.67
Forfeited/canceled	(3,896	)	49.84
Vested	(215,069	)	44.82
Outstanding at March 31, 2020	1,309,835		$	44.36

Unrecognized compensation expense related to RSUs totaled $36.9 million at March 31, 2020 and is expected to be recognized over the remaining weighted-average period of 2.1 years.

Restricted Stock Awards

The Corporation's restricted stock award transactions were as follows:



	Number of Awards		Weighted-Average Grant Date Fair Value Per Award
Outstanding at December 31, 2019	888,305		$	40.67
Forfeited/canceled	(402	)	39.58
Vested	(104,690	)	43.48
Outstanding at March 31, 2020	783,213		$	40.07

At March 31, 2020, there were no shares of performance-based restricted stock awards outstanding. Unrecognized stock compensation expense for restricted stock awards was $15.3 million at March 31, 2020 with a weighted-average remaining amortization period of 2.3 years.

Stock Options

A summary of activity for the Corporation's stock options at and for the three months ended March 31, 2020 is presented below:



	Non-Vested Stock Options Outstanding				Stock Options Outstanding
	Number of Options		Weighted-average Exercise Price		Number of Options		Weighted-average Exercise Price
Outstanding at December 31, 2019	120,809		$	39.63	495,165		$	29.48
Exercised	—		—		(19,274	)	18.18
Forfeited/canceled	(3,173	)	39.00		—		—
Expired	—		—		(34,323	)	34.38
Vested	(55,568	)	38.25		55,568		38.25
Outstanding at March 31, 2020	62,068		$	40.89	497,136		$	30.56
Exercisable/vested at March 31, 2020					497,136		$	30.56

The weighted-average remaining contractual term was 3.9 years for all outstanding stock options and 3.6 years for exercisable stock options at March 31, 2020.